Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

123 results about "Combination Product" patented technology

A product comprised of two or more regulated components, i.e., drug and device, biologic and device, that are physically, chemically, or otherwise combined or mixed and produced as a single entity; or two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products; or a drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or any investigational drug, device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.

Pharmaceutical composition containing PRMT5 inhibitor and kras g12c inhibitor

PCT designated stageWO2025157289A1Antineoplastic agentsPharmaceutical active ingredientsViral OncogeneDisease
A pharmaceutical composition comprising a protein arginine methyltransferase 5 (PRMT5) inhibitor and a KRASG12C (Kirsten rat sarcoma viral oncogene homolog glycine-to-cysteine) inhibitor. The pharmaceutical composition can be used for treating various cancers, comprising solid tumors. The combined product can be used for treating any number of diseases associated with PRMT5 and / or KRASG12C.
Owner:SHANGHAI APEIRON THERAPEUTICS CO LTD

Nucleic acid combination product, kit and method for detecting human infectious diarrhea pathogenic virus

The invention provides a nucleic acid combination product, and a kit and a method for detecting human infectious diarrhea pathogenic viruses. The nucleic acid combination product comprises a composition of one or more groups of primer pairs and detection probes. The nucleic acid combination product has no cross reaction on near-source non-target pathogens and non-target pathogens with the same sampling parts and similar clinical symptoms, each target can reach 10 copies / reaction, and the nucleic acid combination product has high sensitivity and specificity.
Owner:GUANGZHOU BAOCHUANG BIOTECHNOLOGY CO LTD

Nucleic acid combination product, kit and method for detecting various respiratory tract pathogenic bacteria

The invention discloses a nucleic acid combination product, a kit and a method for detecting various respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair and a probe, wherein the sequences of the primer pair and the probe are respectively shown as SEQ ID NO: 1-SEQ ID NO: 24. The nucleic acid combination product realizes synchronous detection of various pathogens through a one-tube eight-color fluorescent PCR, freeze-drying and ultrasonic direct diffusion method technology, significantly reduces experimental operation steps, shortens detection time, reduces the complexity of result interpretation, and has strong anti-interference capability and high sensitivity.
Owner:SANSURE BIOTECH INC

Nucleic acid combination product for detecting multiple respiratory pathogens, kit containing nucleic acid combination product and method

The invention discloses a nucleic acid combination product for detecting various respiratory pathogens, a kit containing the nucleic acid combination product and a method. The nucleic acid combination product comprises a primer pair and a probe, wherein the nucleotide sequences of the primer pair and the probe are respectively shown as SEQ ID NO: 1-21. According to the nucleic acid combination product, on the technical basis of Taqman fluorescent quantification, seven targets can be detected by one tube, so that the time and energy of operators are greatly shortened, and the nucleic acid combination product is convenient and rapid, is not easy to make mistakes, and is simpler and easier to understand in result interpretation.
Owner:SANSURE BIOTECH INC

Pharmaceutical composition containing PRMT5 inhibitor and mat2a inhibitor

A pharmaceutical composition comprising a protein arginine methyltransferase 5 (PRMT5) inhibitor and a methionine adenosyltransferase IIα (MAT2A) inhibitor. The pharmaceutical composition can be used for treating various cancers, comprising solid tumors. The combined product can be used for treating any number of diseases associated with PRMT5 and / or MAT2A.
Owner:SHANGHAI APEIRON THERAPEUTICS CO LTD

Pharmaceutical composition comprising PRMT5 inhibitor and EGFR inhibitor

Disclosed is a pharmaceutical composition, comprising a protein arginine methyltransferase 5 (PRMT5) inhibitor and an epidermal growth factor receptor tyrosine kinase (EGFR) inhibitor. The pharmaceutical composition can be used to treat various cancers, including solid tumors. The combination product can be used to treat any number of diseases associated with PRMT5 and / or EGFR.
Owner:SHANGHAI APEIRON THERAPEUTICS CO LTD

USP1 inhibitor and pharmaceutical use thereof

The present invention relates to a USP1 inhibitor and pharmaceutical use thereof. Specifically, the present invention relates to a combination product comprising a USP1 inhibitor and an additional anti-tumor drug other than the USP1 inhibitor, and pharmaceutical use thereof. The USP1 inhibitor has a structure represented by formula I:
Owner:JIANGSU YAHONG MEDITECH CO LTD +1

Nucleic acid combination product, kit for detecting pathogenic fungi and detection method

The invention relates to a nucleic acid combination product, a kit for detecting pathogenic fungi and a detection method. The nucleic acid combination product provided by the invention comprises a composition of a plurality of groups of primer pairs and detection probes, is wide in detection coverage and high in inclusiveness, can simultaneously detect a plurality of pathogenic fungi in a single-tube reaction system, has relatively high sensitivity and specificity, is a pathogenic fungi detection product with relatively comprehensive detection targets at present, and has a wide application prospect. And an auxiliary diagnosis basis is provided for clinical examination.
Owner:GUANGZHOU BAOCHUANG BIOTECHNOLOGY CO LTD

Otic drug delivery system and methods

Disclosed herein are drug delivery devices including catheter assemblies, infusion systems, pre-filled syringes, methods of use, combination products, kits of parts, and drug products with parts lists for independent sourcing, for use in the otic administration of a drug product to a subject in need thereof.
Owner:REGENERON PHARMACEUTICALS INC

Pharmaceutical composition containing PRMT5 inhibitor and CDK4 / 6 inhibitor

A pharmaceutical composition comprising protein arginine methyltransferase 5 (PRMT5) and cyclin-dependent kinase 4 and 6 (CDK4 / 6) inhibitors. The pharmaceutical composition can be used for treating various cancers, comprising solid tumors. The combined product can be used for treating any number of diseases associated with PRMT5 and / or CDK4 / 6.
Owner:SHANGHAI APEIRON THERAPEUTICS CO LTD

Pharmaceutical combination and use for treating tumors

The present invention relates to a pharmaceutical combination product and a therapeutic use thereof. Specifically, the present invention provides a pharmaceutical combination product comprising a first pharmaceutically active ingredient and a second pharmaceutically active ingredient, wherein the first pharmaceutically active ingredient is a KRAS inhibitor. The present invention also provides a use for treating tumors, comprising administering the pharmaceutical combination product of the present invention to a subject in need.
Owner:SHOUYAO HOLDINGS (BEIJING) CO LTD

Multi-mode fluid delivery device

The present invention relates to a multi-mode fluid delivery device for drugs and vaccines for use in the fields of human clinical care and animal health care. Through the design that multiple needles and multiple holes are matched with the detachable injection head and the needle head piece contained in the detachable injection head, all the advantages of a needle-free injection mode, a micro-needle injection mode and a needle injection mode are combined, the defects of the needle-free injection mode, the micro-needle injection mode and the needle injection mode are eliminated, flexible switching among the needle-free mode, the micro-needle injection mode and the needle injection mode is achieved, and the injection efficiency is improved. The single delivery amount and delivery efficiency of drugs and vaccines are improved while painless and skin injury are avoided, liquid leakage is eliminated, the drugs and vaccines are delivered to one or more target positions with different depths of a human body, the three-dimensional dispersity of the drugs and vaccines at the target positions is controlled, pharmacokinetics is optimized, and the drug delivery efficiency of the drugs and vaccines is improved. Therefore, the contact effect and the bioavailability of the medicine and the vaccine with in-vivo tissues are greatly improved. Related components, systems, and related pharmaceutical and mechanical combinations are also provided.
Owner:BEIJING NOMEDEL DRUG DELIVERY INNOVATION PLATFORM LTD

Anti-CD40 antibodies and their uses

This invention relates to anti-CD40 antibodies or antigen-binding fragments thereof that specifically recognize and weakly activate CD40 molecules in humans, cynomolgus monkeys, and mice, as well as immunoconjugates, pharmaceutical compositions, and combination products comprising said anti-CD40 antibodies or antigen-binding fragments thereof. The invention also relates to nucleic acids encoding said anti-CD40 antibodies or antigen-binding fragments thereof and host cells comprising said nucleic acids, and methods for preparing said anti-CD40 antibodies or antigen-binding fragments thereof. Furthermore, the invention relates to the use of said anti-CD40 antibodies or antigen-binding fragments thereof in the prevention or treatment of tumors or infectious diseases in subjects.
Owner:ANHUI RUBIOX VISION BIOTECH +1

Primer probe combination product for respiratory tract infection detection

The invention relates to the technical field of biology, in particular to a primer probe combination product for respiratory tract infection detection. A plurality of specific primers and self-quenching probes are integrated in a single reaction system; simultaneous, rapid and rapid detection on 15 respiratory pathogens (including influenza A virus, influenza B virus, respiratory syncytial virus, severe acute respiratory syndrome coronavirus 2, mycoplasma pneumoniae, parainfluenza virus, rhinovirus, enterovirus, coronavirus, adenovirus, metapneumovirus, bordetella pertussis, bocavirus, chlamydia pneumoniae and chlamydia psittaci) is realized. The detection is accurate.
Owner:CHINA JAPAN FRIENDSHIP HOSPITAL +2

Composition for protein precipitation, protein precipitation agent containing same, protein precipitation combination product, detection kit, and preparation method and detection method of blood analysis sample

The invention relates to the technical field of biological detection, in particular to a composition for protein precipitation, a protein precipitation agent containing the composition, a protein precipitation combined product, a detection kit and a preparation method and a detection method of a blood analysis sample. The composition for protein precipitation comprises zinc sulfate and ammonium acetate in a dosage ratio of (5-17) mg: (0.5-1) mmol. Compared with the prior art, the composition has the following beneficial effects that the zinc sulfate and the ammonium acetate are matched according to a specific proportion, so that the specific composition is formed, and hemoglobin in a blood sample can be effectively removed by taking the composition as a protein precipitation component.
Owner:RELAIS (HANGZHOU) MEDICAL TECH CO LTD

Smoking system, device kit, consumables, combination products, and method for obtaining end-user sensation and end-user anticipation.

ActiveJP7884112B2MedicineEngineering
To provide a smoking system that when a flavor generation article is inserted into a chamber, allows a user to easily feel arrival at an end of the chamber and to easily foresee that it will arrive at the end of the chamber.SOLUTION: When a resistance value when a flavor generation article is inserted into a storage part and a tip of the flavor generation article arrives at an end of the storage part, is insertion force A, and a ratio of a rear-half average resistance force to a front-half average resistance force is a first resistance ratio B, a smoking system satisfies A≤4.00 N and B>1.0, where the rear-half average resistance value is an average of resistance values from a midpoint between a prescribed position on an insertion end side of the storage part and an end of the storage part to the end of the storage part. and the front-half average resistance force is an average of resistance values from the prescribed position to a midpoint between the prescribed position and the end of the storage part.SELECTED DRAWING: Figure 16
Owner:JAPAN TOBACCO INC

Nucleic acid combination product, kit and method for detecting a plurality of respiratory pathogens

The application discloses a nucleic acid combination product, a kit and a method for detecting multiple respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair and a probe, wherein the sequences of the primer pair are respectively shown as SEQ ID NO:1-SEQ ID NO:24. The nucleic acid combination product realizes the synchronous detection of multiple pathogenic bacteria through one-tube eight-color fluorescence PCR, freeze-drying and ultrasonic direct extension technology, significantly reduces the experimental operation steps, shortens the detection time, reduces the complexity of result interpretation, and has strong anti-interference ability and high sensitivity.
Owner:SANSURE BIOTECH INC

Nucleic acid combination product for detecting SIAH2, diagnostic kit for osteoarthritis and application thereof

The invention belongs to the technical field of biomedicine, and particularly relates to a nucleic acid combination product for detecting SIAH2, a diagnostic kit for osteoarthritis and application of the diagnostic kit. According to the application, the models are established by using machine learning to analyze various cell death modes, and the application finds that in the models of the four cell death modes, the ferroptosis model has the highest diagnosis efficiency on the OA and identifies the corresponding biomarkers. It is found that SIAH2 is used as a biomarker to regulate occurrence and development of OA through cartilage cells, and a new diagnosis and treatment strategy is provided for OA.
Owner:HOSPITAL OF STOMATOLOGY GUANGZHOU MEDICAL UNIVERSITY (YANGCHENG HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY)

A mounting method and device based on combined goods

The present application discloses a mounting method and device based on combination products, the method comprising: rewriting the main product name in the combination product according to the four-level category requirements based on the acquired basic data of the combination product and the product category basic data, to obtain the four-level standardized product name corresponding to the combination product and the four-level category; recalling the four-level category through the first category recall method and the second category recall method according to the four-level standardized product name and the product category basic data, respectively, to recall the first candidate fourth-level category data and the second candidate fourth-level category data corresponding to the four-level standardized product name; mounting the combination product on the fourth-level category data that matches the four-level standardized product name determined based on the first candidate fourth-level category data and the second candidate fourth-level category data, as well as the basic data of the combination product, to achieve end-to-end mapping of the combination product to the four-level category, and to improve the mounting coverage and efficiency of the combination product to the four-level category.
Owner:RAJAX NETWORK &TECHNOLOGY (SHANGHAI) CO LTD

Combination product for relieving the symptoms associated with upper respiratory tract infections

The present invention relates to a combination product comprising, as active substances, at least erysimum, propolis, zinc, ribwort plantain, and marshmallow. The invention also relates to the use of a combination product as defined above for treating the symptoms associated with upper respiratory tract infections. Finally, the invention relates to the use of a combination product as defined above for treating the symptoms associated with throat infections and irritation.
Owner:URGO RECH INNOVATION & DEVEMENT

Methods for evaluating the effectiveness of aerosols for pulmonary drug delivery using inhaler devices, oral inhalation and / or nasal medications, and drug / device combination products.

PendingJP2026521839AInhaled drugEfficacy
The present invention relates to a method for evaluating the effectiveness of an aerosol (3) for pulmonary drug delivery, as well as inhaler devices (2, 2a, 2b, 2c, 2d), orally inhaled drugs (1), and drug / device combination products (7). [Solution] An inhaler device (2, 2a, 2b, 2c, 2d) can generate an aerosol (3), which contains aerosol particles (30) containing an orally inhaled drug (1). The method includes the steps of providing a computational lung model (Lmod) and a computational particle transport and deposition model (Pmod), calculating the spatial particle deposition distribution (Ddist) of discrete particles (30') based on a determined aerosol value (Aval) of an aerosol parameter (Apar), calculating the efficacy value (Eval) of an efficacy parameter (Epar) based on the spatial particle deposition distribution (Ddist), and using the efficacy value (Eval) to automatically evaluate the efficacy of the aerosol (3) for lung drug delivery.
Owner:EBENBUILD GMBH

Nucleic acid combination, kit for identification of mycobacteria and use thereof

This application belongs to the field of molecular biology technology, specifically relating to nucleic acid combo products, kits for mycobacterial identification, and their applications. This application provides a nucleic acid combo product for mycobacterial detection, comprising one or more primer pairs with nucleotide sequences as shown in SEQ ID NO.1 to SEQ ID NO.244. This specific primer combination can simultaneously detect multiple mycobacteria and distinguish them down to the subspecies level. Through highly specific primer design, this nucleic acid combo product can achieve accurate identification of common clinical mycobacteria (including complex groups, species, and subspecies levels), with a detection sensitivity of 50-100 CFU / mL, significantly superior to the detection performance of existing technologies. Furthermore, the nucleic acid combo product of this application can not only identify the species of mycobacteria but also simultaneously detect drug resistance gene mutations, providing important evidence for the selection of clinical treatment regimens.
Owner:广州市胸科医院 +1

New use

PCT designated stageWO2026026944A1Organic active ingredientsRespiratory disorderInterstitial pneumoniasPharmaceutical drug
The present disclosure relates to a new use, and mainly relates to the use of an FAK inhibitor, such as IN10018, in the preparation of a drug for treating or preventing interstitial pneumonia, a method for treating or preventing interstitial pneumonia by means of administering a therapeutically effective amount of the FAK inhibitor, such as IN10018, and a pharmaceutical combination product, kit and pharmaceutical composition containing the FAK inhibitor, such as IN 10018, for treating or preventing interstitial pneumonia.
Owner:INXMED (NANJING) CO LTD

Smoking system, device kit, consumable supply, combination product, and method for acquiring feeling of arrival at end and foreseeing arrival at end

To provide a smoking system that when a flavor generation article is inserted into a chamber, allows a user to easily feel arrival at an end of the chamber and to easily foresee that it will arrive at the end of the chamber.SOLUTION: When a resistance value when a flavor generation article is inserted into a storage part and a tip of the flavor generation article arrives at an end of the storage part, is insertion force A, and a ratio of a rear-half average resistance force to a front-half average resistance force is a first resistance ratio B, a smoking system satisfies A≤4.00 N and B>1.0, where the rear-half average resistance value is an average of resistance values from a midpoint between a prescribed position on an insertion end side of the storage part and an end of the storage part to the end of the storage part. and the front-half average resistance force is an average of resistance values from the prescribed position to a midpoint between the prescribed position and the end of the storage part.SELECTED DRAWING: Figure 16
Owner:JAPAN TOBACCO INC

Nucleic acid combination product, kit for detecting genital tract infection pathogens and detection method

The invention relates to a nucleic acid combination product, a kit for detecting genital tract infection pathogens and a detection method. The nucleic acid combination product provided by the invention comprises a composition of a plurality of groups of primer pairs and detection probes, is wide in detection coverage and high in inclusiveness, can simultaneously detect a plurality of genital tract infection pathogens in a single-tube reaction system, and has relatively high sensitivity and specificity; the kit is a genital tract infection pathogen detection product with comprehensive detection targets at present, can quickly and accurately provide a basis for clinical diagnosis, and provides support for prevention, control and treatment of genital tract infection.
Owner:GUANGZHOU BAOCHUANG BIOTECHNOLOGY CO LTD

Antiviral pharmaceutical composition and preparation method thereof

Provided are an oral pharmaceutical composition comprising a spiro compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a preparation method of the oral pharmaceutical composition, and a combined product comprising the oral pharmaceutical composition and another antiviral drug, the invention also discloses application of the oral pharmaceutical composition and the combination product in resisting virus infection and treating or preventing related diseases caused by virus infection. # imgabs0 #
Owner:HAINAN SIMCERE PHARMA CO LTD

A combination of scyllo-inositol and n-acetyl cysteine and related compounds

The invention relates to the use of scyllo-inositol alone or in combination with other active ingredients including the compound N-acetylcysteine or a derivative thereof to support cognitive health in a subject that takes the product or combination product. The compositions, which are inclusive of oral dosage forms such as tablets or capsules, are provided to the subject which is inclusive of humans or other mammals such as dogs or cats or other animals in need of cognitive improvement. The combination product(s) break up amyloid beta aggregates and promote the clearance of amyloid beta fibrils from the glymphatic system as well as the treatment of disease and conditions that are acerbated by free radicals.
Owner:EIRGEN PHARMA LTD

Methods of treating metabolic disorders and combination products for use in the same

PCT designated stageWO2025238423A2Salicyclic acid active ingredientsMetabolism disorderBenzeneNitroethylene
The present in vention is directed to methods of treating a metabolic disorder in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a nitro-vinyl benzene compound and administering to the subject a therapeutically effective amount of a GLP-1 agonist or analog. The present invention is also directed to kits and / or pharmaceutical compositions suitable for practicing the claimed methods.
Owner:BATTHYÁNY DIGHIERO CARLOS IGNACIO +3

Nucleic acid combination product, PCR premix, method and kit for identifying respiratory tract pathogenic bacteria

The invention relates to the technical field of biological detection, in particular to a nucleic acid combination product, a PCR premix, a method and a kit for identifying respiratory tract pathogenic bacteria. The nucleic acid combination product comprises a primer pair as shown in SEQ ID NO: 1 to SEQ ID NO: 21 and a probe. The invention provides a nucleic acid detection product for detecting klebsiella pneumoniae, streptococcus pneumoniae, haemophilus influenzae, pseudomonas aeruginosa, acinetobacter baumannii, staphylococcus aureus and moraxella catarrhalis, and the nucleic acid detection product can be used for performing amplification detection on conserved fragments of target pathogens in the same PCR reaction system, and is efficient and low in cost. Moreover, the anti-interference capability is strong, and the sensitivity is high.
Owner:SANSURE BIOTECH INC